摘要
肾性贫血是慢性肾衰竭血液透析患者的最常见并发症,其发病机制较为复杂,与铁吸收和利用障碍、促红细胞生成素缺乏、微炎症状态、缺氧诱导因子氧传感途径异常及营养不良等因素共同作用有关。补铁、输血或补充外源性促红细胞生成素是目前治疗肾性贫血的有效手段。此外,新型临床药物缺氧诱导因子-脯氨酰羟化酶抑制剂、铁调素通路抑制剂等亦为该病治疗提供了新的方向。深入分析肾性贫血的发病机制,尽早识别其发生危险因素并进行干预,以及全面了解当前治疗手段,对该病的临床预防和治疗具有重要意义。
Renal anemia is the most common complication in patients with chronic renal failure undergoing hemodialysis,the pathogenesis of which is complex and related to joint actions of multiple factors such as iron absorption and utilization disorders,erythropoietin deficiency,micro-inflammatory state,hypoxia-inducible factor oxygen sensing pathway abnormalities and malnutrition.Iron supplementation,blood transfusion or exogenous erythropoietin supplementation are currently effective means for the treatment of renal anemia.In addition,new clinical drugs such as hypoxia-inducible factor-prolyl hydroxylase inhibitor and hepcidin pathway inhibitor also provide new directions for the treatment of this disease.In-depth analysis of the pathogenesis of renal anemia,early identification of related risk factors and intervention,as well as a comprehensive understanding of the current treatment methods are of great significance for the clinical prevention and treatment of this disease.
作者
高雪
杨莉
苏东美
GAO Xue;YANG Li;SU Dongmei(Department of Nephrology,West China Hospital,Sichuan University,Chengdu 610044,China)
出处
《医学综述》
CAS
2023年第12期2423-2427,共5页
Medical Recapitulate
关键词
慢性肾衰竭
血液透析
肾性贫血
Chronic renal failure
Hemodialysis
Renal anemia
作者简介
通信作者:高雪,Email:sallyxue00@163.com。
